Company ProfilePremium

Cellumed Co., Ltd.

Company Profile Analysis

Ticker: 049180.KQ주식회사 셀루메드

ESOMAR 23 Corporate BadgeISO Certifications Badge
Cellumed Co., Ltd. - Company showcase

Year Founded & Workforce

1985

55 Employees

Cellumed Co., Ltd. logo

Cellumed Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Cellumed Co., Ltd. Overview

Cellumed is a Seoul-based medical-device and tissue-biologics company. It started as an industrial firm (Newtechman), listed on KOSDAQ in 2002, and took on its musculoskeletal and biologics identity through the 2010 merger with Korea Bone Bank. Its medical franchise rests on licensed human-tissue banking. Key products include demineralized bone matrix (Rafugen DBM, Rafugen Dental), acellular dermal matrix (the CELLUDERM family), recombinant human BMP-2 and FGF growth factors, and a titanium-alloy total-knee system. In economic terms, however, the group is now mostly a building-services contractor. Its subsidiary Hwangyeong ENG (환경이엔지), which does mechanical and fire-protection installation, produced about 93% of consolidated revenue in Q2 2026. The equity story since 2025 has been driven by solvency, not operations. A US royalty judgment, capital impairment, administrative-issue designation, repeated non-clean auditor review opinions, a change of control to an investment partnership, and a pending KRX delisting review now matter more to the valuation than product performance.


What the company does

Cellumed operates two economically distinct businesses within one listed shell.

(a) Medical / biologics (parent company). Cellumed holds a human tissue bank licence (granted 2005) and a licence to manufacture human-tissue-based medical devices (granted 2007). Under these it processes donated human tissue into:

Bone graft materials: demineralized bone matrix (DBM) in gel and powder forms for orthopaedic and spinal fusion (Rafugen DBM, Rafugen DBM Gel Pro), and dental bone graft (Rafugen Dental, also called Dental Powder).

Skin / soft-tissue grafts: acellular allogeneic dermis (CELLUDERM HD IMPLANT, CELLUDERM POWER, CELLUDERM ULTRA). Injectable forms, CELLUDERM FILL and CELLUDERM GEN, have completed development. These are used in breast reconstruction, plastic surgery, urology and "men's/women's medicine" indications.

The company also makes:

Recombinant protein biologics: rhBMP-2 (bone morphogenetic protein 2, used for bone regeneration). Cellumed describes itself as the second company in the world and the first in Asia to mass-produce rhBMP-2. It also makes FGF (fibroblast growth factor, including FGF7), which is used as a cosmetic ingredient.

Orthopaedic implants and instruments: a total-knee replacement whose femoral and tibial components are both titanium alloy (claimed to be the first such domestically produced product in Korea), spinal fixation systems, navigation systems, and 3D-printed patient-specific instruments (PSI) for knee arthroplasty.

Cosmeceuticals: the Dermycos (더미코스) line based on FGF7. It was listed at Shilla Duty Free in 2021.

Exploratory programmes: enzymes used to produce mRNA vaccines and therapeutics, through subsidiary Cellumed Biologics (founded August 2022 in Songdo, Incheon) and contract development with a German partner. In 2023 the company also announced plans for swappable-battery packs and electric two-wheelers.

(b) Construction machinery & equipment installation (subsidiaries). In 2019 Cellumed acquired InsGreen (인스그린, environmental-facilities construction) and Hwangyeong ENG (환경이엔지, general mechanical/building-services installation). Hwangyeong ENG installs HVAC, plumbing and fire-protection systems as a subcontractor to Korea's top-tier general contractors. Its projects include apartment complexes (including an LH Korea Land & Housing site in Wonju), commercial buildings (a department store renovation in Daegu) and infrastructure (Korean Air Incheon T2-related works). It reported record revenue above KRW 100 bn in FY2024 and an order backlog of about KRW 140 bn in December 2025 (Asia Economy, 4 December 2025).

Business and revenue model

DimensionMedical / biologicsConstruction equipment installation
Revenue typeProduct sales (tissue grafts, implants, devices, proteins, cosmetics)Contract revenue, recognised by percentage of completion on subcontracted installation work
CustomersUniversity and specialist hospitals, orthopaedic and spine surgeons, dental clinics and networks, plastic surgery and breast surgery clinics; overseas distributors for DBMTop-tier Korean general contractors (named as a "preferred partner" by several); public housing (LH); commercial developers
PricingLargely regulated by Korea's national health-insurance reimbursement for reimbursed items; specific prices not publicly disclosedCompetitive tender / negotiated subcontract
Value-chain positionTissue processor and manufacturer (sources donor tissue, partly from global suppliers per the company); also an R&D originator for recombinant proteinsSpecialist subcontractor below general contractors
Approximate revenue share~7% of consolidated revenue (Q2 2026)~93% of consolidated revenue (Q2 2026)

Product vs. service vs. subscription vs. licensing mix: in substance, almost all revenue is either product sales (medical) or contract/service revenue (construction). No subscription or licensing revenue is disclosed. Notably, the company has been a payer of royalties: the US Buechel-Pappas litigation relates to royalties owed for artificial-joint technology.

Company's own description vs. independent characterisation

  • Company's own framing (paraphrased from the FY2025 Business Report and press releases): Cellumed calls itself a bio-medical-device manufacturer. It traces its lineage to Newtechman (1985), its KOSDAQ listing (2002), and the 2010 Korea Bone Bank merger, which took it into medical devices and biosimilars. Its press releases consistently use the label "bio medical device specialist manufacturer" (바이오 의료기기 전문 제조기업). The DART industry classification is basic pharmaceutical substances and biological products manufacturing.

Independent characterisation: By revenue, Cellumed is a building-services contractor with an attached, sub-scale tissue-biologics franchise. The medical business shrank from KRW 14.6 bn (FY2022) to KRW 14.1 bn (FY2023) and KRW 8.6 bn in 9M2024 (Dealsite, March 2025). Meanwhile construction grew to more than 87% of revenue. The medical assets (licences, FDA-listed DBM, rhBMP-2 process know-how, ADM line) carry strategic option value. This was shown by L&C Bio Group's interest in December 2025, which was later abandoned. But the medical business is not large enough to carry group overheads, litigation costs or financing needs.

Strategy

Stated strategic themes (paraphrased from FY2025-era company statements)

Following the January 2026 recapitalisation, the company stated five priorities (Asia Economy, 21 January 2026):

  1. Systematic management of financial risk, with litigation debt repaid first.

  2. Stabilising the internal organisation.

  3. Reorganising the business portfolio around profitability.

  4. Making production and supply of core products more efficient.

  5. Expanding distribution and partnerships.

The new largest shareholder said it would take an active management role and pursue new bio businesses that create synergies with the existing ones. Management called 2026 the "first year" of an earnings turnaround (Asia Economy, 30 December 2025).

Initiatives announced in the last 24 months (Oct 2024 – Oct 2026)

DateInitiativeDescription / targetStatusSource
Late 2024 – Feb 2025Production-process task force (생산공정 TFT)Company-wide quality and process programme; DBM capacity more than 2xCompleted February 2025Asia Economy, 9 April 2025
Apr 2025ISO 13485 recertificationQuality system covering bone-formation products and the knee systemAchievedAsia Economy, 9 April 2025
May–Jun 2025Production-led reorganisation; global raw-material sourcingRecord monthly output (May) and record monthly sales (June) for bone graftsAchieved (monthly records)Asia Economy, 29 May & 30 June 2025
Aug 2025CELLUDERM HD IMPLANT upgrade; CELLUDERM FILL and GEN completedClinician-driven product improvement; targeting H2 2025 sales expansionCompletedAsia Economy, 19 August 2025
Aug 2025Litigation settlementSettled the US award for KRW 16.56 bn, framed as removing management riskPartly paid; renegotiated in 2026Asia Economy, 18 August 2025
Oct–Dec 2025Sale of control via placementInitially a KRW 20 bn third-party placement; first L&C Bio, then TD LandmarkCompleted January 2026 (KRW 17 bn)Dealsite
Dec 2025 (abandoned)L&C Bio integration planCombine Cellumed's DBM, BMP and FGF technology with L&C Bio's ECM regenerative platform; existing management to acquire and spin off non-medical assetsWithdrawn 29 December 2025Dealsite, 23 December 2025
Jan 2026Hwangyeong ENG 2026 operating policyZero serious accidents and site-centred risk management; more top-tier contractor awardsOngoingAsia Economy, 27 January 2026
Mar 2026Settlement reschedulingRetain specialist counsel; seek staggered payments; review a contribution claim against former management (co-defendant)In negotiation; amended agreement disclosed 30 June 2026Hankyung, 3 March 2026; IRGO

ESG / sustainability commitments: none disclosed.

Cost programmes with targets: none disclosed.

Medium-term financial targets / guidance

No formal quantitative guidance has been published. Qualitative statements include:

  • Expectations that 2025 would deliver record consolidated revenue. This proved correct: KRW 140.2 bn.

  • Hwangyeong ENG's backlog of about KRW 140 bn supporting continued growth (Asia Economy, 4 December 2025).

  • 2026 framed as a turnaround year.

Products & Services

Medical / biologics segment

Product / brandCategoryDescription & key capabilitiesTarget customerLaunch / latest versionPricingSource
Rafugen DBM (라퓨젠 DBM)Bone graft (allograft, demineralized bone matrix)Gel-type DBM with high DBM content, intended to speed bone formation in bone defects. Company states US FDA clearance. Flagship product; process upgrade in 2025 more than doubled capacityOrthopaedic and spine surgeons; hospitals; overseas distributorsOn market; capacity upgrade completed February 2025—Asia Economy, 9 April 2025; Dealsite, 10 March 2025
Rafugen DBM Gel ProBone graftGel DBM variant shown on the company website (marketed as bone for biomaterial transplantation)Orthopaedics / spine——Dealsite, 17 April 2025
Rafugen Dental (라퓨젠 덴탈) / Dental PowderDental bone graftAllograft powder for dental bone augmentation; co-flagship with Rafugen DBM; record monthly output May 2025Dental clinics and networksExpanded line 2023—Asia Economy, 29 May 2025; Etoday, 12 June 2023
Bone sponge, bone powderBone graftAllograft bone substitutes for regenerationOrthopaedics——GuruFocus description
CELLUDERM HD IMPLANTSkin graft (acellular dermal matrix)Allogeneic ADM, mainly used in breast reconstruction; cutting precision and finishing upgraded in August 2025 based on clinician feedbackBreast and plastic surgeonsProcess upgrade August 2025—Asia Economy (English), 19 August 2025
CELLUDERM POWERADMIndication-specific ADM variantPlastic / reconstructive surgery——Asia Economy, 19 August 2025
CELLUDERM ULTRAADMIndication-specific ADM variantPlastic / reconstructive surgery——Asia Economy, 19 August 2025
CELLUDERM FILLInjectable ADMMicronised ADM in injectable form, aimed at reconstruction indicationsBreast reconstruction surgeonsDevelopment completed September 2024—FY2025 Business Report; Asia Economy, 4 September 2024
CELLUDERM GENInjectable ADMInjectable ADM with a different ratio of purified water or biocompatible polymer carrier; intended for different, broader indicationsPlastic surgery; aesthetic / other indicationsDevelopment completed by August 2025—Asia Economy, 4 September 2024 & 19 August 2025
Allograft tissue range (hard tissue, soft tissue, skin, spinal spacers, bio-cleanant)AllograftTissue-bank-processed human tissue for transplantationHospitalsOngoing—EMIS profile
rhBMP-2 reagent / BMP-2 based products (incl. BMP2 DBM gel)Recombinant protein biologicRecombinant human BMP-2 for bone regeneration; Cellumed claims to be the 2nd company worldwide and 1st in Asia to develop and mass-produce itSpine / orthopaedics; research users——Dealroom; EMIS; GuruFocus
FGF / FGF7 recombinant proteinsRecombinant proteinGrowth-factor proteins used in cosmeceutical formulations and skin regeneration R&DCosmetic brands; internal use——Asia Economy, 15 November 2021; Dealsite, 23 December 2025
Dermycos (더미코스)CosmeceuticalFGF7-based skincareDuty-free and export (China) consumersListed at Shilla Duty Free in 2021—Asia Economy, 15 November 2021
Titanium total knee replacementOrthopaedic implantFemoral and tibial components both in titanium alloy, described as Korea's first such domestic product; claimed to be more than 2x lighter than cobalt-chrome designsOrthopaedic surgeonsISO 13485 recertified April 2025—Asia Economy, 9 April 2025; Dealroom
PSI (patient-specific instruments)Surgical instruments3D-printed, patient-matched instruments for total-knee arthroplasty; AI/robotic integration targetedOrthopaedic surgeonsClinical expansion from 2021—Asia Economy, 26 March 2021 & 15 March 2023
Joint-replacement surgical robot (distribution)Capital equipmentSales of a knee-arthroplasty robot announced in 2021 (manufacturer not disclosed)Hospitals2,021—Asia Economy, 26 March 2021
Spinal fixation systemsImplantPedicle-screw style spinal fixationSpine surgeons——GuruFocus; EMIS
Navigation systemSurgical deviceOrthopaedic navigationHospitals——GuruFocus; EMIS
Knee cartilage / tissue-engineering productsTissue engineeringDemineralized bone and knee-cartilage R&DOrthopaedicsR&D stage—Asia Economy, 3 September 2024
Stem-cell / bio-engineering productsR&DListed as a portfolio category; no commercial product identified———EMIS

Exploratory / non-core initiatives

InitiativeDescriptionStatusSource
mRNA production enzymesEnzymes for in-vitro transcription in mRNA vaccine and therapy manufacturing; contract development with a German party; production through Cellumed BiologicsPreparing for mass production in 2022; no commercial revenue disclosedAsia Economy, 16 August 2022 & 3 September 2024; PatSnap
Swappable battery packs and e-two-wheelersBattery solutions sourced from a Chinese battery company; local pack assembly; import and assembly of e-two-wheelersBusiness objects added in 2023; still described as an ongoing pursuit in March 2024Asia Economy, 15 March 2023 & 7 March 2024
AI-assisted surgical roboticsIntegrating PSI with AI robotics through partnershipsAspirational; no product disclosedAsia Economy, 15 March 2023

Construction segment services (Hwangyeong ENG / InsGreen)

Service lineDescriptionRecent referencesSource
Mechanical installation (HVAC, plumbing)Heating, cooling and air-conditioning systems for residential and commercial buildingsKRW 4.1 bn HVAC works for a large department-store renovation in Daegu (awarded December 2025; works from 2026)Asia Economy, 4 December 2025
Fire-protection systemsSprinkler and fire-suppression installationNamed as a core capabilityAsia Economy, 4 December 2025
Public housing worksInstallation for LH apartment projectsLH Wonju apartment project (2025)Asia Economy, 4 December 2025
Infrastructure / aviationWorks related to the Korean Air Incheon T2 IOC project2025 awardAsia Economy, 4 December 2025
Environmental facilities (InsGreen)Environmental plant constructionAcquired 2019Dealsite, 10 March 2025

Financial Narrative

Data limitations. Full consolidated statements for FY2021–FY2025 could not be downloaded from DART. The income-statement headline figures below come from Butler.works, which aggregates DART filings, and are cross-checked against Stockopedia (revenue) and press reports. Gross profit, EBITDA, EPS, cash flows and most balance-sheet lines are not available from the sources reviewed and are left blank. Investors should also note that the auditor issued a disclaimer of opinion on the H1 2025 and H1 2026 review reports, so the reliability of reported figures is itself in question.

Income statement (consolidated)

Sources: Butler.works (DART-derived) for revenue, operating income and net income FY2021–FY2025. FY2024 revenue, operating loss and net loss are also confirmed by Digital Today's DART summary (KRW 129.1 bn / -6.8 bn / -31.8 bn). Margins and growth rates are computed. The FY2021 growth rate uses the company-reported FY2020 revenue of KRW 91.5 bn (Asia Economy, 26 March 2021).

Revenue CAGR FY2021–FY2025: 8.8% (computed: 140.2 / 99.9 over four years).

Longer history (pre-diversification) — FY2018–FY2020

Sources: FY2019 audit report summary (filed 19 March 2020) for FY2018–FY2019; Asia Economy (26 March 2021) for FY2020. Standalone FY2020: revenue KRW 16.5 bn (+29% YoY), operating loss KRW 1.6 bn (KRW 7.9 bn better YoY).

Balance sheet

Source: Digital Today DART summary for FY2024 (assets KRW 70.2 bn, liabilities KRW 61.2 bn, equity KRW 9.1 bn; the small arithmetic gap is due to rounding).

Other balance-sheet datapoints:

Borrowings due within one year: KRW 8.9 bn. This is the latest figure cited by Dealsite on 11 March 2025, probably FY2024 year-end.

Share capital: was KRW 27.5 bn before the January 2026 placement. A 5:1 reverse split was discussed in the market as a way to cut it to KRW 5.5 bn, but management denied pursuing it (Dealsite, 21 October 2025). After the placement and CB conversions, share capital was KRW 41.6 bn (FY2025 Business Report).

March 2021 post-recapitalisation metrics: current ratio 123% and debt ratio (liabilities/equity) 63.7%, after KRW 41.4 bn of funding including a KRW 34.9 bn placement (Asia Economy, 26 March 2021).

Capital impairment: at FY2024 year-end, the capital-impairment ratio was 50% or more. A capital-impairment ratio of 50% or more (or equity below KRW 1 bn) was confirmed again at H1 2026 (KRX disclosure, 14 August 2026).

Cash flow

Line-item cash flows are not publicly disclosed in the sources reviewed. In March 2025, Dealsite reported that operating cash flow had been persistently negative and that cash outflows were becoming entrenched. Buybacks: none identified; the treasury-share ratio is 0.01% (Butler.works).

Equity financing history (third-party placements)

Sources: FY2025 Business Report (Feb 2021 KRW 13.92 bn; Feb 2024 KRW 10.00 bn; Sep 2024 KRW 2.00 bn; Apr 2025 KRW 5.00 bn). The January 2026 placement of KRW 17.0 bn falls in FY2026. The FY2025 report also notes a KRW 17.0 bn placement decision dated 10 February 2026 with TD Landmark Union No. 1 as subscriber. It is unclear whether this is a second placement or a dating of the same transaction; it is flagged as unresolved.

Ratios

FY2024 ratios are computed from the Digital Today DART summary. ROE on year-end equity is not meaningful at this level of impairment and is shown only to illustrate scale.

Aggregator ratio snapshots (dates uncertain; shown only for completeness):

  • GuruFocus: cash-to-debt 0.5; equity-to-asset 0.43; debt-to-equity 0.31; Piotroski F-score 3/9; Altman Z-score -0.17; 3-year revenue growth -4.1%. The snapshot is from a period when the share price was KRW 2,035, earlier than FY2024.

  • Stockopedia: ROE -87.5%; operating margin -19.7%; P/B 8.66; P/S 0.95.

  • StockHub (October 2026): ROE -55.7%; P/B 3.30; TTM P/E 25.2.

  • Butler.works: P/B 3.30; P/E 31.4.

The positive TTM P/E readings conflict with reported net losses. They may reflect a one-off provision reversal in a trailing period and should not be relied on.

Commentary on trends, inflections and drivers

FY2021 (peak profitability). Revenue reached KRW 99.9 bn and operating income KRW 4.7 bn, the best year in the period. Construction contributed KRW 76.1 bn, and the medical business recovered as orthopaedic surgery volumes rebounded after COVID-19. Management also credited tighter receivables management (Asia Economy, 15 November 2021).

FY2022 (top-line high, margin turn). Revenue rose 22% to KRW 122.1 bn as construction reached KRW 90.4 bn. But the group slipped to an operating loss of KRW 2.7 bn. Management blamed sharp increases in raw-material and subcontracting costs (InTheNews, 16 August 2022).

FY2023 (contraction and large net loss). Revenue fell 22% to KRW 95.6 bn as construction dropped to KRW 76.5 bn amid a Korean construction downturn. The operating loss widened to KRW 10.5 bn. The KRW 37.9 bn net loss was much larger than the operating loss, which implies large non-operating charges. Management also said capacity expansion temporarily constrained medical supply in H1 2023 (Etoday, 12 June 2023).

FY2024 (record revenue, continued losses). Revenue rebounded 35% to KRW 129.1 bn, driven by Hwangyeong ENG passing KRW 100 bn. Medical revenue fell again, which management attributed to the government–doctor dispute. The KRW 31.8 bn net loss most likely reflects recognising the US judgment liability (about KRW 24 bn) as a provision. Year-end equity fell to KRW 9.1 bn.

FY2025 (record revenue, net loss nearly eliminated). Revenue rose to a record KRW 140.2 bn, and the operating loss narrowed to KRW 5.1 bn. The net loss shrank to KRW 2.2 bn. This is consistent with the company's statement that the gap between the court award (about KRW 24 bn) and the August 2025 settlement (KRW 16.56 bn) would be written back to income (Asia Economy, 18 August 2025). The underlying operating business remained loss-making.

Structural observations:

  1. Consolidated margins are those of a low-margin subcontractor. Hwangyeong ENG earned operating profit of only about KRW 1 bn-plus on revenue above KRW 100 bn in FY2024, roughly a 1% margin (Dealsite, 21 October 2025).

  2. The parent's medical business was profitable at the operating level only briefly (9M2021).

  3. Since 2019, the company has relied on repeated third-party placements, about KRW 70 bn in total including 2021's KRW 34.9 bn and 2026's KRW 17.0 bn, to stay solvent.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityRelationshipBusinessStatus / notesSource

Cellumed Co., Ltd.

Listed parent

Tissue grafts, implants, recombinant proteins, cosmeceuticals

KOSDAQ 049180; trading suspended

FY2025 Business Report

Hwangyeong ENG (환경이엔지)

Principal subsidiary (100% per 2021 report)

Mechanical and fire-protection installation

—

Asia Economy, 26 March 2021 & 4 December 2025; Dealsite, 21 October 2025

InsGreen (인스그린)

Subsidiary (acquired 2019)

Environmental-facilities construction

—

Dealsite, 10 March 2025

Cellumed Biologics (셀루메드 바이오로직스)

Subsidiary (founded August 2022)

R&D and CDMO for mRNA-production enzymes

—

Asia Economy, 16 August 2022

Revenue by Segment and Revenue by Segment (%)

MetricFY2019FY2020FY2021FY2022FY2023

Construction machinery & equipment revenue (KRW Bn)

3.952.776.190.476.5

Medical devices revenue as reported (KRW Bn)

———14.614.1

Other / residual revenue, derived (KRW Bn)

———17.15.0

Total consolidated revenue (KRW Bn)

17.991.599.9122.195.6

Construction share of total (%)

21.857.676.274.080.0

Construction revenue growth YoY (%)

—1,251.344.418.8-15.4

Construction by Period

PeriodConstruction (KRW Bn)Medical (KRW Bn)Total (KRW Bn)Construction share (%)Source

9M2024

80.78.692.587.3

Dealsite, 10 March 2025

Q2 2026

———

93 (medical 7)

Butler.works (DART segment data)

“—” = not publicly disclosed.

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

99.9122.195.6129.1140.2

Revenue growth YoY (%)

9.222.2-21.735.08.6

Operating income (KRW Bn)

4.7-2.7-10.5-6.8-5.1

Net income (KRW Bn)

8.4-5.4-37.9-31.8-2.2

Dividends per share (KRW)

00000

Operating margin (%)

4.7-2.2-11.0-5.3-3.6

Net margin (%)

8.4-4.4-39.6-24.6-1.6

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Balance Sheet

MetricFY2018FY2019FY2020

Revenue (KRW Bn)

9.917.991.5

Operating income (KRW Bn)

-10.9-8.02.4

Pre-tax income from continuing operations (KRW Bn)

-8.5-36.5—

Net income (KRW Bn)

-9.8-37.31.8

Total assets (KRW Bn)

49.665.0—

Total liabilities (KRW Bn)

26.649.3—

Total equity (KRW Bn)

23.015.7—

Share capital (KRW Bn)

10.212.2—

Revenue History

PeriodRevenue (KRW Bn)Operating income (KRW Bn)OtherSource

9M2021 (consolidated)

86.83.5

Standalone 9M revenue 10.0; standalone operating income 1.4

Asia Economy, 15 November 2021

H1 2022 (consolidated)

63.6-0.4

Record H1 at the time; standalone revenue up more than KRW 10 bn YoY

InTheNews / Asia Economy, 16 August 2022

9M2024 (consolidated)

92.5—

Construction 80.7; medical 8.6

Dealsite, 10 March 2025

9M2025 (consolidated)

—-4.5

Loss widened YoY

Dealsite, 28 January 2026

Q1 2026

——

EPS -21.85 (KRW)

Investing.com

Balance Sheet (FY2024)

MetricFY2024

Total assets (KRW Bn)

70.2

Total liabilities (KRW Bn)

61.2

Total equity (KRW Bn)

9.1

Financial Analysis

MetricFY2021FY2022FY2023FY2024FY2025

Dividends paid (KRW Bn)

00000

Share buybacks (KRW Bn)

00000

Balance Sheet (FY2021–FY2025)

MetricFY2021FY2024FY2025

Third-party equity placements completed (KRW Bn)

13.912.05.0

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2024

ROE (%), on year-end equity

-349.5

ROA (%), on year-end assets

-45.3

Liabilities / equity (x)

6.7

Equity / assets (%)

13.0

Asset turnover (x)

1.84

Share Price History

DatePrice (KRW)EventSource

Sep 2024 (4th)

2,295

+16.5% on CELLUDERM FILL completion

Asia Economy, 4 September 2024

25 Aug 2025

572

Close, after the appeal withdrawal

Digital Today, 25 August 2025

16 Oct 2025

805

Close on the day of the unfaithful-disclosure notice

Digital Today, 16 October 2025

26 Dec 2025

1,896

+29.95% intraday

Twig24 / Seoul Shinmun

30 Dec 2025

1,154

-29.98% (limit-down) after L&C Bio withdrawal

Asia Economy, 30 December 2025

Last trade before suspension

1,009

Trading suspended (delisting process)

Investing.com; StockHub; Butler.works

52-week range (pre-suspension)

542 – 2,975

—

Investing.com

Metric

1-year

3-year

5-year

Share price change (%)

11.6——

Capital Markets

MetricCellumedPeer referenceSource

Market cap (KRW Bn)

about 84.0

L&C Bio about 1,365

Butler.works

P/E (TTM)

25.2 – 31.4 (aggregators; inconsistent with reported losses; treat as unreliable)

L&C Bio: not meaningful (net loss)

StockHub; Butler.works

P/B (x)

3.30

L&C Bio 4.20

Butler.works

EV/EBITDA (x)

Not meaningful (EBITDA not disclosed; operating loss)

——

Capital Markets — Buyback authorisations

ItemStatusSource

Buyback authorisations

None identified; treasury shares 0.01%

Butler.works

Moody's / S&P / Fitch ratings

Not rated

—

Domestic credit ratings

Not identified

—

Debt maturity profile

Not publicly disclosed. KRW 8.9 bn of borrowings was due within one year as of the latest period cited in March 2025

Dealsite, 11 March 2025

Capital Markets Data

MetricFY2018FY2019FY2025 (post-period, Apr 2026)

Share capital (KRW Bn)

10.212.241.6

Analyst Conclusions

Management guidance

No quantitative guidance is published. Management described 2026 as the start of an earnings turnaround and pointed to continued growth at Hwangyeong ENG, supported by a backlog of about KRW 140 bn (Asia Economy, 30 December 2025 & 4 December 2025).

Consensus

No sell-side consensus exists.

Bull case

  1. Construction keeps growing revenue. Hwangyeong ENG's backlog of about KRW 140 bn and repeat awards from top-tier contractors underpin revenue above KRW 140 bn. Even a 1–2% margin at this scale offsets parent overhead if medical losses narrow.

  2. The medical assets are worth more than the listed shell implies. L&C Bio's December 2025 attempt to pay KRW 17 bn for about 34% shows strategic interest in Cellumed's DBM, BMP, FGF and ADM capabilities. At a market cap of about KRW 84 bn with about KRW 14 bn of medical revenue, a resolution could lead to a re-rating or an asset sale.

  3. Litigation can be capped. Settling at KRW 16.56 bn (versus about KRW 24 bn) produced an accounting write-back. If the June 2026 amendment holds and the remaining payments are completed, the main source of the 2023–2025 losses is gone, and a recourse claim against former management could recover part of the cost.

Bear case

  1. Delisting risk dominates. Shares are suspended under a KRX improvement period. The second consecutive half-year disclaimer (August 2026) cited going concern and the recoverability of loans receivable. Under the 2025 rule reform, repeated sub-standard opinions accelerate delisting.

  2. Use of new money is uncertain. Reports that KRW 14.0 bn of the KRW 17.0 bn placement went to external parties, together with the auditor's concerns about loan recoverability, suggest the recapitalisation may not have strengthened the balance sheet as intended. Meanwhile settlement payments were missed (March 2026).

  3. The core business is weak. Four straight years of operating losses (FY2022–FY2025), medical revenue down to about 7% of the mix, falling R&D, and growing competition in ADM and ECM limit any standalone recovery. Equity has been repeatedly impaired despite about KRW 70 bn of placements since 2021.

Key catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timingWhy it matters
KRX decision at the end of the improvement periodlikely tied to the FY2026 annual audit cycle (March–April 2027)Determines whether the shares are delisted or trading resumes
FY2026 annual audit opinionMarch 2027A clean opinion is a precondition for resuming trading
Outcome of the EGM (board reconstitution under TD Landmark)Pending (notice corrected repeatedly through 27 August 2026)Clarity on governance and control
Compliance with the amended settlementOngoing (amendment disclosed 30 June 2026)A default could revive a liability of about KRW 24–26 bn
Clarification of placement-proceeds flows and loans receivableOngoingCore to the auditor's concerns
Whether the Hwangyeong ENG buy-back by InsCobee happensReported condition, within one yearCould remove about 93% of revenue from the consolidated group
Q3 2026 quarterly reportBy mid-November 2026Updated equity and cash position
Commercial uptake of CELLUDERM FILL and GEN2026–2027The medical growth thesis

Concluding analyst verdict

Cellumed has to be analysed as a distressed listed holding company, not as an orthopaedic-biologics growth story. Its medical franchise is real. It holds tissue-bank and tissue-device licences dating from the mid-2000s, a DBM product described as FDA-cleared whose capacity doubled in 2025, recombinant rhBMP-2 and FGF know-how, a domestic titanium knee, and a refreshed acellular-dermis line that now includes injectable forms. A credible strategic buyer, L&C Bio, came close to paying KRW 17 bn for about a third of the company in December 2025. Those assets have value.

But the medical business now produces only about 7% of consolidated revenue. The group's KRW 140 bn top line is almost entirely low-margin subcontracted building-services work, and consolidated operating income has been negative every year from FY2022 to FY2025. The balance sheet has been repeatedly impaired. Equity was KRW 9.1 bn at FY2024 year-end, and capital impairment of 50% or more was re-confirmed at H1 2026.

The investment case depends on three binary outcomes. The first is the KRX delisting process now under an improvement period. The second is the auditor's ability to issue a clean FY2026 opinion after two half-year disclaimers that cited going concern and loan recoverability. The third is performance under the amended Buechel-Pappas settlement. The January 2026 recapitalisation was meant to resolve the litigation and stabilise operations, but it was followed by missed settlement instalments and unconfirmed reports that most of the proceeds left the company. That weakens confidence in governance.

On the evidence available, the downside scenarios, delisting or further dilution, are at least as likely as a clean recovery. Until the auditor's concerns and the delisting review are resolved, the reported market capitalisation of about KRW 84 bn cannot be treated as a tradable or reliable valuation. For counterparties such as suppliers, distributors and partners, the most relevant questions are continuity of supply and contract enforceability, not upside. Cellumed is best treated as a special-situation monitor, not a fundamental investment candidate.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameRoleTenure / datesBackgroundSource

Yoo In-soo (유인수)

Representative Director (CEO)

CEO until 2 April 2021; co-CEO from 9 June 2021; named as sole Representative Director in the FY2025 report (April 2026)

—

FY2025 Business Report; Asia Economy, 7 March 2024

Lee Seok-hwan (이석환)

Former CEO / co-CEO

—

Former CEO of SK Telecom China; former president of SK Networks ICT; led InsCobee's telecom (MVNO) business

Asia Economy, 5 April 2021

Yoo Jun-young (유준영)

Head of Planning Office; responsible officer for the FY2025 report

Current

—

FY2025 Business Report

Kim Ki-ho (김기호)

Statutory auditor (감사)

Elected 31 March 2025

—

FY2025 Business Report

Kang Pan-heon (강판헌)

Former statutory auditor

Left 31 March 2025

—

FY2025 Business Report

Kang Yong-ju (강용주)

Vice President (former spokesperson for the bio business)

Quoted 2022–2023

—

InTheNews, 2022; Etoday, 2023

Lee Byung-gil (이병길)

Inside director; Head of Strategic Business (battery/EV)

Nominated March 2023

Several years as an executive at global telecom and electronics firms in China and Hong Kong

Asia Economy, 15 March 2023

Noh Doo-hyun (노두현)

Outside director

Nominated March 2023

Professor of Orthopaedic Surgery, Seoul National University Hospital (BS, MS and PhD from SNU College of Medicine); founder of AI medical-robot company Connecteve

Asia Economy, 15 March 2023

Park Hyung-seop (박형섭)

Outside director

In office during 2024

—

Dealsite, 17 April 2025

Choi Jeong-seok (최정석), Kim Jin-yeol (김진열), Yoo Chang-soo (유창수)

Former Representative Directors (dates of appointment partially visible)

——

FY2025 Business Report (fragment)

Shim Young-bok (심영복)

Founder-era former CEO and former largest shareholder

Largest shareholder until April 2018

Named as co-defendant in the Buechel-Pappas judgment

FY2025 Business Report; Dealsite, 11 March 2025

“—” = not publicly disclosed.

Board & Management Changes

DateChangeContextSource

Apr 2018

Largest shareholder: Shim Young-bok → InsCobee

Takeover by InsCobee

FY2025 Business Report

2 Apr 2021

CEO: Yoo In-soo → Lee Seok-hwan

After trading resumed

Asia Economy, 5 April 2021

9 Jun 2021

Co-CEOs Yoo In-soo and Lee Seok-hwan

—

FY2025 Business Report

Mar 2023

Lee Byung-gil (inside) and Noh Doo-hyun (outside) join

Push into battery/EV and robotics

Asia Economy, 15 March 2023

31 Mar 2025

Auditor: Kang Pan-heon → Kim Ki-ho

AGM

FY2025 Business Report

20–27 Jan 2026

Largest shareholder: InsCobee → TD Landmark Union No. 1; business manager appointed

KRW 17 bn placement

Dealsite, 28 January 2026; IRGO

Major Shareholders

HolderSharesStake (%)NotesSource

TD Landmark Union No. 1 (티디랜드마크조합1호)

28,192,370

about 33.9

Investment partnership established in 2025; described as having a bio-industry network and as related to Cellumed's business; ultimate beneficial owners not disclosed

Asia Economy, 30 December 2025; Dealsite, 16 January 2026

InsCobee Inc. (and related parties)

—

about 14 (press estimate)

Held 22.2% in March 2021; about 8.77 million shares locked up to March 2024; added 5,359,057 shares in 2024. Press estimated its stake at about 14% after the 2026 placement

Asia Economy, 5 April 2021 & 7 March 2024; Dealsite, 21 October 2025

Treasury shares

—0.01—

Butler.works

Competitive Landscape

Key Competitors

CompetitorOverlap with CellumedScale indicatorSource

L&C Bio (엘앤씨바이오, KOSDAQ 290650)

Allograft tissue, ADM (MegaDerm), ECM injectables (ELRAVIE Re2O)

FY2025 revenue KRW 85.5 bn; operating income KRW 4.4 bn; market cap about KRW 1.36 trillion

Butler.works; Alphadistill

Hans Biomed (한스바이오메드)

Allograft skin and bone, ECM skin boosters

—

Alphadistill (as an ECM entrant)

CGBio (시지바이오)

Bone grafts; rhBMP-2 products; ECM boosters

—

Alphadistill (as an ECM entrant)

GC Wellbeing (GC녹십자웰빙)

ECM skin boosters

—

Alphadistill

Osteonic (오스테오닉)

Orthopaedic / dental implants and biomaterials

—

Shinhan peer list (September 2025)

Corentec (코렌텍)

Artificial joints (knee and hip)

—

Shinhan peer list (September 2025)

L&K Biomed (엘앤케이바이오)

Spinal implants

—

Shinhan IR report (September 2025)

Key Competitors — Medtronic

CompetitorOverlap with CellumedSource

Medtronic

rhBMP-2 (INFUSE), spine

—

Johnson & Johnson (DePuy Synthes)

Joints, spine, biologics

Shinhan peer list

Globus Medical

Spine, biologics

Shinhan peer list

Stryker, Zimmer Biomet

Knee arthroplasty, robotics

—

US tissue banks (MTF Biologics, LifeNet Health, AlloSource)

DBM and ADM allografts

—

Peer Comparison FY2025

MetricCellumed (FY2025)L&C Bio (FY2025)

Revenue (KRW Bn)

140.285.5

Revenue growth YoY (%)

8.618.6

Operating margin (%)

-3.65.1

Net income (KRW Bn)

-2.2

-138.2 (non-cash derivative losses)

R&D intensity (%)

not disclosed for FY2025 (2.5 in FY2023)

—

Market cap (KRW Bn)

about 84 (suspended)

about 1,365

Company Snapshot

$98.7M

Revenue

55

Employees

1985

Founded

SWOT Analysis

Strengths

  • Regulatory licences: tissue-bank licence (2005) and tissue-device manufacturing licence (2007), giving a regulated, hard-to-replicate franchise (Asia Economy, 29 May 2025).
  • Export-grade DBM: Rafugen DBM is described as US FDA-cleared, and its capacity more than doubled in February 2025 (Asia Economy, 9 April 2025).
  • Recombinant-protein heritage: claimed second-in-world and first-in-Asia mass production of rhBMP-2 (Dealroom).
  • Quality system: ISO 13485 recertified in April 2025 (Asia Economy, 9 April 2025).
  • Construction cash generation at scale: Hwangyeong ENG had record revenue above KRW 100 bn in FY2024, KRW 92.6 bn in 9M2025, and a backlog of about KRW 140 bn (Asia Economy, 4 December 2025).
  • Record consolidated revenue: KRW 140.2 bn in FY2025 (Butler.works).

Weaknesses

  • Persistent operating losses: four straight years, FY2022–FY2025 (-2.7, -10.5, -6.8 and -5.1 KRW bn) (Butler.works).
  • Very low equity: KRW 9.1 bn at FY2024 year-end against liabilities of KRW 61.2 bn; capital impairment of 50% or more re-confirmed at H1 2026 (Digital Today; KRX disclosure, 14 August 2026).
  • Medical business has shrunk: from KRW 14.6 bn (FY2022) to KRW 8.6 bn (9M2024); now about 7% of revenue (Dealsite; Butler.works).
  • Declining R&D: from KRW 3.3 bn (FY2021) to KRW 2.4 bn (FY2023) (Dealsite, 10 March 2025).
  • Governance lapses: outside directors attended 4 of 23 board meetings in 2024 (Dealsite, 17 April 2025); an unfaithful-disclosure designation notice was issued in October 2025 (Digital Today).
  • Audit reliability: H1 2025 and H1 2026 review disclaimers (Money Today; Asia Economy, 18 August 2026).

Opportunities

  • Injectable ADM launches: CELLUDERM FILL and GEN target growing reconstruction and aesthetic demand (Asia Economy, 19 August 2025).
  • Normalising surgical volumes in Korea after the 2024–25 doctor dispute, which management blamed for weak device sales (Dealsite, 10 March 2025).
  • Strategic value of medical assets: L&C Bio's December 2025 offer showed industry interest in Cellumed's DBM, BMP, FGF and recombinant technology (Dealsite, 23 December 2025).
  • Recourse claim: a possible contribution claim against former management, a co-defendant in the US judgment (Hankyung, 3 March 2026).
  • New controlling shareholder's bio agenda: TD Landmark has stated an intention to add synergistic bio businesses (Asia Economy, 21 January 2026).
  • Construction backlog: about KRW 140 bn, plus commercial-facility references such as the Daegu department-store work (Asia Economy, 4 December 2025).

Threats

  • Delisting: a KRX delisting process with an improvement period granted 21 April 2026, and a second half-year disclaimer in August 2026 (IRGO; Asia Economy).
  • Litigation relapse: missed settlement instalments could revive the original award of about KRW 24 bn, or as much as KRW 26 bn by one estimate (Dealsite, 22 December 2025 & 16 March 2026).
  • Use-of-proceeds allegations: reports that KRW 14.0 bn of placement proceeds went to external parties (TheVC news aggregation; unconfirmed).
  • Competitive intensity in ADM and ECM, plus tighter oversight by Korea's Ministry of Food and Drug Safety (Alphadistill).
  • Construction downturn and margin compression: the subsidiary earns only about KRW 1 bn of operating profit on more than KRW 100 bn of revenue (Dealsite, 21 October 2025).
  • Further dilution: about KRW 70 bn of equity raised since 2021, and the share count rose to 83.2 million by April 2026 (FY2025 Business Report).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
7 Apr 2025Seoul Southern District Court issues garnishment and assignment order; the government and 17 banks are barred from paying Cellumed Dealsite, 17 April 2025Cash collection disrupted; administrative-issue cure compromised
9 Apr 2025ISO 13485 recertification; DBM capacity more than 2x Asia Economy, 9 April 2025Supports the medical-segment growth case
Apr 2025KRW 5.0 bn third-party placement FY2025 Business ReportInterim liquidity
16–17 Apr 2025Press highlights poor outside-director attendance in 2024 Dealsite, 17 April 2025Governance concern
22 May 2025Further garnishment and assignment order Digital Today, 25 August 2025Additional receivables seized
29 May 2025Record monthly bone-graft production (May) Asia Economy, 29 May 2025Operational improvement
13 Jun 2025Disclosure of the court decision (garnishment and assignment order) Digital Today (disclosure history)Formal disclosure
30 Jun 2025Record monthly bone-graft sales (June), helped by domestic orders and exports Asia Economy, 30 June 2025Operational improvement
25 Jul 2025Appeal filed against the 22 May order Digital Today, 25 August 2025Legal defence
14 Aug 2025H1 2025 review: disclaimer of opinion Money Today, 18 August 2025Non-clean opinion; risk to listing
18 Aug 2025Settlement with Buechel-Pappas parties at KRW 16.56 bn, payable within 3 months; KRW 2.0 bn already seized, leaving about KRW 14.5 bn to pay Asia Economy, 18 & 19 August 2025Cuts the liability by about KRW 7.4 bn; expected income write-back
18 Aug 2025Parent InsCobee receives its own H1 disclaimer, attributed to the Cellumed exposure; one-day trading halt Asia Economy, 18 August 2025Contagion to parent
19 Aug 2025CELLUDERM HD IMPLANT process upgrade; FILL and GEN development completed Asia Economy (English), 19 August 2025Portfolio refresh
25 Aug 2025Appeal against the garnishment order withdrawn Digital Today, 25 August 2025Consistent with the settlement
19 Sep 2025Withdrawal of a small public-offering placement decided on 20 March 2025 Digital Today, 16 October 2025Led to an unfaithful-disclosure notice
16 Oct 2025Notice of planned designation as an unfaithful-disclosure company (reversal of a disclosure); decision deadline 10 November 2025 Digital Today, 16 October 2025–
17–21 Oct 2025Company confirms it is pursuing a sale of control via a KRW 20 bn placement; denies plans for a 5:1 capital reduction Dealsite, 21 October 2025Change-of-control process
Nov 2025KRW 1.5 bn settlement instalment paid Dealsite, 22 December 2025Partial compliance
4 Dec 2025Hwangyeong ENG wins KRW 4.1 bn Daegu department-store HVAC works; 9M2025 subsidiary revenue KRW 92.6 bn; backlog about KRW 140 bn Asia Economy, 4 December 2025Construction momentum
19–22 Dec 2025KRW 6.0 bn settlement instalment due by end-December; default risk could raise the liability to as much as KRW 26 bn Dealsite, 22 December 2025Liquidity stress
23 Dec 2025L&C Bio Group agrees to lead a KRW 17 bn placement Dealsite, 23 December 2025Strategic buyer emerges
26 Dec 2025Shares rise 29.95% (daily limit) intraday Twig24 / Seoul Shinmun, 26 December 2025Speculative trading
29–30 Dec 2025Placement subscriber changed to TD Landmark Union No. 1; payment date moved to 22 January 2026; shares fall to the daily limit-down at KRW 1,154 (-29.98%) Asia Economy, 30 December 2025Loss of a strategic buyer
15 Jan 2026Payment date brought forward to 20 January; KRW 14.0 bn pre-paid Dealsite, 16 January 2026Deal certainty improves
20 Jan 2026KRW 17.0 bn placement fully paid Asia Economy, 21 January 2026Change of control completed
27 Jan 2026Largest-shareholder change disclosed; business manager appointed; InsCobee says the Cellumed risks are now off its books; Hwangyeong ENG reports top-tier contractor wins two years running Dealsite, 28 January 2026; Asia Economy, 27 January 2026; IRGOGroup separation from InsCobee
3 Mar 2026Company says KRW 6.6 bn of a KRW 17.6 bn settlement total has been paid (including amounts already seized); seeks rescheduling; reviews a contribution claim against former management Hankyung, 3 March 2026Settlement under strain
13–16 Mar 2026Press reports missed settlement payments; risk that the original award of about KRW 24 bn revives Dealsite, 16 March 2026Litigation risk re-ignites
–Press questions the flow of KRW 14.0 bn of placement proceeds to Primecore and DHX Company TheVC news aggregationGovernance and use-of-proceeds concern (unconfirmed)
31 Mar 2026KRX "other market guidance (delisting-related)" notice IRGODelisting process begins
6 Apr 2026FY2025 Business Report filed: revenue KRW 140.2 bn; operating loss KRW 5.1 bn; net loss KRW 2.2 bn KRX KIND; Butler.worksAnnual results
21 Apr 2026KRX accepts the delisting objection; improvement period granted; trading-suspension period changed accordingly IRGOListing preserved for now; shares remain suspended
15 May 2026Q1 2026 quarterly report filed (EPS -21.85 KRW) IRGO; Investing.comContinued losses
28 May 2026Correction to a disclosure of a lawsuit filing above the materiality threshold IRGO–
30 Jun 2026Correction disclosure: amendment to the enforcement-judgment settlement agreement IRGO–
10 Jul 2026Corrected FY2025 Business Report filed IRGO–
14 Aug 2026H1 2026 report; review disclaimer (bases: scope limitation on opening balances, recoverability of loans receivable, going-concern uncertainty); capital impairment ≥50% Butler.works; Asia Economy, 18 August 2026Second consecutive half-year disclaimer; heightened delisting risk
27 Aug 2026Latest correction to the EGM convening notice Butler.worksBoard / control agenda unresolved

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Revenue by Segment: Total consolidated revenue rose from KRW 17.9 Bn in FY2019 to KRW 95.6 Bn in FY2023.
Cellumed Co., Ltd. — Revenue by Segment
Series (KRW Bn)FY2019FY2020FY2021FY2022FY2023
Total consolidated revenue17.991.599.9122.195.6
Construction machinery & equipment revenue3.952.776.190.476.5
Medical devices revenue as reported———14.614.1
Other / residual revenue———17.15

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Cellumed Co., Ltd., FY2025 Business Report (사업보고서, 41st period), filed 6 April 2026 — KRX KIND (kind.krx.co.kr)
  2. Cellumed FY2019 audit report summary (filed 19 March 2020) (financialreports.eu)
  3. IRGO Cellumed IR room (disclosure list 2025–2026) (m.irgo.co.kr)
  4. Butler.works, Cellumed company page (financial summary, segment mix, disclosures) (butler.works)
  5. Butler.works, L&C Bio company page (butler.works)
  6. Investing.com (Korean and Japanese pages), Cellumed quote (kr.investing.com)
  7. StockHub, 049180 (stockhub.kr)
  8. Stockopedia, 049180 (stockopedia.com)
  9. GuruFocus, XKRX:049180 summary (sgp.gurufocus.com)
  10. TheVC, Cellumed profile (thevc.kr)
  11. PatSnap, Cellumed company profile (discovery.patsnap.com)
  12. Dealroom, Cellumed profile (app.dealroom.co)
  13. EMIS, Cellumed company profile (emis.cn)
  14. Dealsite: articles 137758 (10 March 2025), 137852 (11 March 2025), 138238 (14 March 2025), 139818 and 139887 (17 April 2025), 149680 (21 October 2025), 153641 (22 December 2025), 153798 (23 December 2025), 155057 (16 January 2026), 155717 (28 January 2026), 158337 (16 March 2026) (dealsite.co.kr)
  15. Asia Economy (아시아경제): 26 March 2021; 5 April 2021; 15 November 2021; 16 August 2022; 15 March 2023; 7 March 2024; 3–4 September 2024; 9 April 2025; 29 May 2025; 30 June 2025; 18–19 August 2025; 4 December 2025; 30 December 2025; 21 January 2026; 27 January 2026; 18 August 2026 — /: core.asiae.co.kr · view.asiae.co.kr
  16. Hankyung (한국경제), 3 March 2026 (hankyung.com)
  17. Money Today (머니투데이), 18 August 2025 (mt.co.kr)
  18. Digital Today AI disclosure articles, 25 August 2025 and 16 October 2025 (digitaltoday.co.kr)
  19. Etoday, 12 June 2023 (etoday.co.kr)
  20. InTheNews, 16 August 2022 (inthenews.co.kr)
  21. Twig24 / Seoul Shinmun data lab, 26 December 2025 (twig24.com)
  22. Alphadistill, L&C Bio research note (alphadistill.com)
  23. Asia Economy / KB Securities on L&C Bio, 31 July 2025 (core.asiae.co.kr)
  24. Shinhan Investment IR report on L&K Biomed (peer list), 8 September 2025 — file.alphasquare.co.kr
  25. Samil PwC, IPO and delisting reform brief (2025) (pwc.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.